Find Academic Supervisors

Professor Joy Ho is a Clinical Professor of Medicine at the University of Sydney’s Central Clinical School and a Senior Staff Specialist in Haematology at Royal Prince Alfred Hospital (RPAH). She serves as Director of Research and Head of the Multiple Myeloma Research Unit and Thalassemia/Haemoglobinopathy Unit at the Institute of Haematology, RPAH. Her research focuses on multiple myeloma, lymphoma, thalassemia, and iron metabolism, with a strong emphasis on clinical trials and translational medicine. She has led numerous multi-centre trials, including pioneering studies on CAR-T cell therapy for lymphoma and novel therapies for myeloma. Prof Ho’s education includes MB.BS. (Hons) from Sydney, D.Phil (Oxford), and fellowships from the Royal Australasian College of Physicians (RACP) and Royal College of Pathologists of Australasia (RCPA). She has held leadership roles in major hematology organizations, including the International Myeloma Working Group (IMWG) and the American Society of Hematology (ASH). Her international collaborations span Singapore, Thailand, and the United States. Her research interests include: Multiple Myeloma: Developing therapies targeting tumor microenvironment and immune modulation. Lymphoma: Pioneering CAR-T cell therapy in Australia. Thalassemia: Gene therapy and iron chelation advancements, including the landmark Northstar trial. Iron Metabolism: Investigating hepcidin and its role in transfusion-dependent anemias. Her recent publications highlight breakthroughs in CAR-T efficacy, myeloma biomarkers, and thalassemia management. Awards include the 2019 Sydney Local Health District Clinical Trial Award and election to the International Myeloma Society Board. She has secured over $2 million in grants for cutting-edge equipment and research. Prof Ho’s academic contributions extend to teaching and supervision, training fellows for RACP/RCPA certifications. Her leadership in national registries (e.g., Australian Haemoglobinopathy Registry) and guidelines (e.g., iron chelation protocols) underscores her commitment to advancing hematology care globally.

• Multiple Myeloma
• Lymphoma
• Thalassemia
• +5 more

Dr. Faith Kwa is a Senior Lecturer and Course Director for the seven Bachelor of Health Science degrees at Swinburne University of Technology's School of Health Sciences. Her teaching interests include Research Methods, Pathology, and Molecular Biology. She leads the Drug Discovery for Chronic Diseases Laboratory and has been recognized as one of Australia's leading educators, receiving the 2024 citation for Outstanding Contributions to Student Learning by the Australian Awards for University Teaching. Her educational background includes: Doctor of Philosophy from The University of Melbourne, Australia Graduate Certificate in Tertiary Teaching and Learning from RMIT University, Australia Bachelor of Biomedical Science from The University of Melbourne, Australia Bachelor of Science (Honours - First Class) from The University of Melbourne, Australia Fellow of the Higher Education Academy, United Kingdom (2020-present) Dr. Kwa is a molecular biologist whose research focuses on drug discovery for chronic diseases, particularly in the areas of epigenetic medicine, molecular mechanisms of action, and chronic disease prevention and management. Her laboratory has made significant contributions to understanding treatment strategies for leukemia, posterior eye diseases, and Friedreich's ataxia using natural compounds with epigenetic properties. She has made novel observations regarding low doses of epigenetic modifiers in combination therapies that potentiate cytotoxicity in leukemia cells resistant to conventional chemotherapeutic drugs. Her work with sulforaphane (a broccoli-derived compound) has shown therapeutic benefits across multiple disease models, particularly for neurodegenerative and ocular conditions. Analysis of her recent publications reveals a strong focus on neurodegenerative disorders (particularly Friedreich's ataxia), ophthalmic diseases, and molecular approaches to disease treatment. Her work consistently bridges basic science with clinical applications, often examining epigenetic mechanisms and oxidative stress pathways. A recurring theme across her research is the therapeutic potential of natural compounds like sulforaphane, which appears in multiple disease contexts from mitochondrial myopathies to posterior eye diseases. Her scientific recognition includes: 2024 citation for Outstanding Contributions to Student Learning by the Australian Awards for University Teaching 2023 Vice-chancellor's Award for Teaching Excellence (Higher Education - Individual) 2023 School of Health Science Teaching Excellence Award Fellow of the Higher Education Academy in the UK 18 other teaching accolades throughout her academic career Dr. Kwa supervises PhD and Master's students in areas related to molecular mechanisms of disease and therapeutic interventions. She has coordinated and taught eleven different subjects with student numbers ranging from 20 to over 300. As a Chief Investigator, she has secured various learning and teaching grants from Australian universities. Currently, she holds funding for 'Pre-clinical investigations on sulforaphane to advance the cure for Friedreich's ataxia' from the University of Melbourne (2022-2025). She is passionate about developing pedagogical methods to enhance teaching and learning environments and has received positive student feedback throughout her career. Dr. Kwa leads the Drug Discovery for Chronic Diseases Laboratory, where her team investigates potential treatments for various chronic disorders. She also serves as the Swinburne Women Academic Network Leader in the Career Development Team, where she develops programs supporting women academics in progressing their careers. Her laboratory work utilizes pre-clinical disease models to evaluate therapeutic approaches, with a particular emphasis on targeted therapies with superior efficacy for treating human diseases.

• Research Methods
• Pathology
• Molecular Biology
• +7 more

John Reynolds is an Adjunct Associate Professor (Research) at the Australian Centre for Blood Diseases, within the Faculty of Medicine, Nursing and Health Sciences at Monash University. He is also affiliated with The Alfred Hospital, where he serves as Senior Expert Biostatistician in the Department of Clinical Haematology. His work bridges academic research and clinical practice, focusing on statistical design and analysis in hematology and oncology. Current Affiliation: Monash University & The Alfred Hospital Role: Adjunct Associate Professor (Research), Senior Expert Biostatistician Academic Background: PhD in Statistics with Minor in Genetics, North Carolina State University Prior Experience: Peter MacCallum Cancer Centre, Novartis AG, Deakin University John Reynolds' research is centered on biostatistics in clinical oncology, particularly in hematological malignancies. His primary areas of interest include the design and analysis of clinical trials across all phases, with a strong focus on multiple myeloma, chronic myeloid leukemia, and immune thrombocytopenia. He has contributed significantly to projects involving liquid biopsy, minimal residual disease assessment, and the integration of patient-reported outcomes in clinical decision-making. His early-career work involved statistical design in food and agricultural sciences, showcasing a broad methodological foundation. The recent publications and ongoing projects reveal a consistent trend in applying advanced statistical methods to improve risk stratification, treatment efficacy, and early detection in blood cancers. His work frequently appears in high-impact hematology journals such as Blood , Haematologica , and Blood Advances , reflecting his leadership in biostatistical applications in clinical research. He is actively involved in major research initiatives, including the GLAM study on genomic liquid biopsy in multiple myeloma and trials focused on alcohol use disorders. His contributions are primarily as a Chief Investigator in large collaborative studies, emphasizing his central role in trial design and data interpretation. Invited speaker, American Society of Hematology, Clinical Research Training Institute (2023–2025) Invited speaker, CML Opinion Leader Training (2023) Invited speaker, iCMLf - CML Preceptorship (2019) John Reynolds leads and contributes to numerous federally funded research grants, including projects supported by the Department of Health and Aged Care (Australia). His collaborative network spans institutions in Australia and internationally, with active roles in multi-center clinical trials. He is instrumental in mentoring and advising research teams on statistical rigor, trial design, and data analysis. His lab and team involvement is embedded within the Biostatistics Consulting Platform at Alfred Health and Monash University, where he supports a wide range of clinical research projects.

• Biostatistics
• Oncology Clinical Trials
• Hematology
• +12 more

Eduardo Eyras is a Professor at the Australian National University (ANU) and EMBL Australia Group Leader, leading research in computational RNA biology and cancer genomics. He directs the Centre for Computational Biomedical Sciences and is part of the Shine-Dalgarno Centre for RNA Innovation. His work focuses on transcriptome and epitranscriptome analysis using long-read sequencing, machine learning, and computational methods to study cancer mechanisms. Eyras holds a PhD in Mathematics from the University of Groningen (1999) and previously led research at the Sanger Institute and Pompeu Fabra University. Affiliations: Director, Centre for Computational Biomedical Sciences Researcher, Shine-Dalgarno Centre for RNA Innovation Member, Division of Genome Sciences and Cancer Leader, The Eyras Group - Computational RNA Biology Research Interests: Development of algorithms for long-read sequencing Machine learning applications in RNA biology Epitranscriptomic modifications and cancer Therapeutic mRNA platform steering Key Projects: Novel algorithms for transcriptome variation analysis Predictive models of RNA modifications in disease Ribosomal DNA variation analysis Advisees & Grants: Supervises PhD students (e.g., Favour Oyelami, Stefan Prodic) and leads ARC-funded projects on mRNA diagnostics and epitranscriptomic therapies. Collaborates with global teams on forensic genomics, cancer drug resistance, and AI-driven translational research. Labs/Teams: Leads the Eyras Group, collaborating with the Hannan Group (Cancer Therapeutics) and Shirokikh Group (Protein Biosynthesis).

• RNA Biology
• Cancer Research
• Long-read Sequencing Technologies
• +4 more

Andrew Zannettino is the Executive Dean of the Faculty of Health and Medical Sciences at the University of Adelaide. He holds the academic rank of Professor of Experimental Haematology and co-directs the Myeloma Research Laboratory at SAHMRI. His research focuses on multiple myeloma, bone cancer, and mesenchymal stem cell biology, with significant contributions to patents underlying Mesoblast Ltd's regenerative therapies. He has led over AUD $35 million in grants, including NHMRC, ARC, and industry-funded projects. Key achievements include identifying mechanisms of myeloma-associated bone loss, developing novel biomarkers, and pioneering stem cell therapies. He actively collaborates with global institutions and serves on advisory boards for Myeloma Australia and AusHealth Pty Ltd. Education: Advanced qualifications in Haematology and Molecular Biology (details not explicitly provided). Research Interests: Myeloma pathogenesis, stem cell therapeutics, bone microenvironment, and clinical translation. Awards: Over 300 publications, H-index 73, and recognition as a NHMRC Grant Review Panel member. Grants: Extensive funding from NHMRC, Cancer Australia, and industry partners like Novartis and Mesoblast. His leadership roles include chairing research committees and strategic initiatives at the University of Adelaide. Professional activities include global conference presentations and editorial roles in top journals.

• Multiple Myeloma
• Bone Cancer Research
• Stem Cell Biology
• +3 more

Dr. Kavitha Gowrishankar is a Senior Lecturer in Immunology at the University of Sydney's School of Medical Sciences, under the Faculty of Medicine and Health. She is affiliated with the Westmead Institute for Medical Research, Kids Research (The Children's Hospital Westmead), and Sydney Cancer Partners. Her research focuses on adoptive cell therapy, CAR T-cells for cancers like leukemia, lymphoma, multiple myeloma, and pediatric solid tumors (sarcoma, brain cancer), as well as T cell receptor engineering and HIV viral reservoir eradication. She has pioneered the use of piggyBac transposase for T-cell genetic modification and investigated combination therapies targeting melanoma and other malignancies. Academic Background: PhD in Immunology (University of Sydney, 2005–2008) Research Training (Indian Institute of Science, India, 1992–1995) Master of Science in Bio-Medical Genetics (University of Madras, India, 1990–1992) Bachelor of Science in Botany (University of Madras, India, 1987–1990) Schooling in India (1975–1987) Research Interests: Her work bridges basic immunology and translational applications. She explores CAR T-cell engineering for pediatric and adult cancers, particularly targeting the tumor microenvironment and latent HIV reservoirs in CD4 T cells. Key innovations include optimizing transposon tools for CAR insertion and developing strategies to enhance CAR T-cell efficacy against solid tumors. She also investigates epigenetic regulators (e.g., BET/HDAC inhibitors) to combat melanoma resistance mechanisms. Articles Trends: Recent publications emphasize CAR T-cell safety (e.g., lymphoma risks), novel CAR designs (e.g., piggyBat transposase), and combination therapies targeting HIV reservoirs. Her work spans preclinical studies to clinical trials, with a focus on melanoma, myeloma, and pediatric sarcomas. She frequently collaborates on projects involving T-cell receptors and interferon modulation strategies. Awards: APA Scholarship (2005–2008) CSIR Research Fellowship (India, 1992–1995) Gold Medallist in M.Sc. (Bio-Medical Genetics, 1992) Gold Medallist in B.Sc. (Botany, 1990) Advising & Grants: Supervises PhD students in CAR T-cell applications for HIV and pediatric sarcomas. Leads grants including the E2CAR Trial (Phase I clinical trial for EphA2-targeted CAR T-cells in sarcoma), and collaborations targeting dual-specific CAR T-cells for HIV eradication. Her grants reflect a mix of preclinical and clinical translational research. Labs & Teams: Active in the Westmead Institute for Medical Research and Kids Research. Collaborates with the Sydney Cancer Partners consortium, focusing on novel cellular therapies and cross-disciplinary oncology solutions.

• Adoptive Cell Therapy
• CAR T-cells
• Cancer Immunology
• +9 more

Professor Jake Shortt is a leading academic in haematology, serving as Head of Haematology Research at Monash University's School of Clinical Sciences and Clinical Director of Monash Health Haematology. He specializes in translational research focusing on epigenetic drugs combined with immunotherapy for haematological cancers, particularly lymphoma and multiple myeloma. His roles include Principal Investigator on multiple clinical trials for T-cell lymphoma and myeloid malignancies, and leadership in initiatives like the Monash Health Research Strategy Committee. His research spans clinical trials, drug development (e.g., luspatercept, asciminib), and molecular oncology with a focus on MYC-driven cancers. He holds honorary positions at the University of Melbourne and Peter MacCallum Cancer Centre. Awards include the NHMRC Emerging Leadership Fellowship and multiple research prizes. Key collaborations involve institutions globally, with projects addressing MDS, CML, and immunotherapeutic strategies. Recent work emphasizes combination therapies, genomic approaches in diagnosis (e.g., RNA fusion panels), and addressing treatment resistance in cancers like AML and T-cell lymphoma. His lab, Blood Cancer Therapeutics at Monash Health Translation Precinct, bridges bench-to-bedside innovation.

• Cancer Immunology
• Epigenetics
• Leukemia
• +6 more

Dr. Jacqui McGovern is a Senior Research Fellow at Queensland University of Technology (QUT) in the Faculty of Health, School of Biomedical Sciences. With a PhD and Bachelor of Applied Science (Honours) both from QUT, she has established herself as an interdisciplinary researcher at the forefront of biomaterials and tissue engineering for cancer research. Dr. McGovern specializes in developing in vitro and in vivo models of bone metastatic cancers (including breast and prostate cancer) and bone-resident tumours such as osteosarcoma and multiple myeloma. Her expertise in 3D tissue models of complex organs , particularly skin and bone, allows her to investigate fundamental interactions between cancer cells and the human bone microenvironment. This research has significant implications for improving the quality of life for patients affected by metastatic cancer. Analysis of Dr. McGovern's publication record reveals a strong trajectory of high-impact research focused on humanized bone models for cancer studies. Her work spans multiple disciplines including tissue engineering, cancer biology, and biomaterials science, with particular emphasis on prostate cancer bone metastasis, osteosarcoma, and the role of bone marrow adipocytes in cancer progression. The interdisciplinary nature of her research bridges engineering, biology, and clinical applications. Dr. McGovern has received significant research support from prestigious organizations: International Myeloma Foundation Cancer Australia Advance Queensland As an academic supervisor, Dr. McGovern has guided numerous PhD and Master's students through their research journeys. Her current supervisions include projects on tissue engineering humanized rat models for osteosarcoma research and analysis of scaffold-based tissue engineering techniques. She has successfully completed supervisions on humanized bone sarcoma models, targeted therapeutic strategies against cancer bone metastasis, and convergence of bioengineering with orthopaedics and tumour biology. Her research is further supported by major grants including the Humanized Rat Models project (2021) and the ARC Training Centre for Cell and Tissue Engineering Technologies (2019). Dr. McGovern is actively involved with the Centre for Biomedical Technologies at QUT and collaborates extensively with Distinguished Professor Dietmar W Hutmacher and other researchers. Her laboratory work focuses on developing advanced biomaterial platforms and humanized animal models to study cancer-bone interactions and test novel therapeutic approaches. The integration of engineering principles with cancer biology represents the cutting-edge nature of her research program.

• Tissue Engineering
• Biomaterials
• Cancer Research
• +7 more

Associate Professor Claudia Rutherford is a clinical research methodologist at Chris O'Brien Lifehouse and the University of Sydney, specializing in patient-reported outcomes (PROs), health-related quality of life (HRQL), and symptom burden in research and clinical practice. With over 15 years of experience, she serves as Director of the Sydney Quality of Life Office (SQOLO), which she re-established in 2023 to optimize the use of PROs in health research and routine healthcare, ensuring the patient perspective informs care, research, and decision-making. Her research interests focus on: Clinical research in implementing routine PRO collection in health settings for individual patient decision-making and service evaluation Methodological research to improve PRO/HRQL research standards from concept development through peer-review reporting Rutherford's recent publications (2023-2025) demonstrate a strong focus on patient-reported outcome measures across various healthcare contexts, with particular emphasis on oncology applications. Her work spans systematic reviews, psychometric evaluations, cross-cultural validations, and implementation studies, with significant contributions to immune checkpoint inhibitors, cancer survivorship, bladder cancer, and integration of PROs into routine clinical care. She frequently collaborates on international initiatives aimed at standardizing PRO methodology and implementation, particularly through her leadership in the SISAQOL-IMI project. Her scientific recognition includes: Novice Investigator Award of EPUAP for 2010 New Investigator Poster Presentation Award of ISOQOL 2014 As an educator, Rutherford coordinates and lectures for OLEO5623 Quality of Life Research Principles at the University of Sydney since 2018, lectures for AMED3001 Cancer Unit of Study at Westmead since 2018, and serves as a guest lecturer on patient-reported outcomes at Sydney Nursing School since 2016. She supervises research students including Margaret TAIT, who is researching health-related quality of life in patients accessing medicinal cannabis. Rutherford also chairs the Patient-Reported Outcomes Special Interest Group with over 1000 members and contributes to the Primary Care Collaborative Cancer Clinical Trials Group (PC4). Rutherford leads several significant research projects including: Strengthening Healthcare Systems with Patient Reported Outcome Measures (PROMs) - NHMRC 2021 Partnership Projects PRC3 Identifying referral pathways for a nurse-delivered sexual function and intimacy service for cancer patients - Cancer Institute NSW Clinical Trials Portfolio MY-PROMPT-2 trial for relapsed multiple myeloma - NHMRC MRFF Rare Cancers ACORNS Program of Research (2018-2023) - Beckett Fellowship SISAQOL-IMI - International Standards of PROs in Cancer Clinical Trials

• Patient-Reported Outcomes (PROs)
• Health-Related Quality of Life (HRQL)
• Clinical Research Methodology
• +5 more

Dr Vasilios Panagopoulos is an NHMRC Ext-Funded Research Fellow and Group Leader at the University of South Australia (UniSA), holding an Affiliate Senior Lecturer role at the University of Adelaide and a Faculty Fellowship at SAHMRI. His research focuses on the tumor microenvironment's role in cancer progression, particularly in prostate, breast, and multiple myeloma cancers. He leads the Prostate Tumour Microenvironment and Therapeutics Lab under Prof. David Waugh, aiming to translate findings into clinical applications. Research Interests : - Prostate cancer immunosuppression via IKKα inhibition and MPO regulation. - Vitamin D analogues for aggressive breast cancer. - Bone marrow microenvironment in multiple myeloma progression. - Novel therapies targeting stromal factors like Gremlin1 and CCR1. Awards and Funding : - Secured $1.8M in competitive grants (NHMRC, Cancer Australia). - 2021 Derek Frewin Early-Career Researcher Award. - 2017 Ross Wishart Memorial Award. - Multiple travel grants for conference presentations. Collaborations : - Global partnerships with Oxford University, AstraZeneca, and Washington University. - National collaborations with Garvan Institute and UniSA. Lab and Teams : Leads the Prostate Tumour Microenvironment and Therapeutics Lab, focusing on IKKα inhibitors, vitamin D analogues, and MPO inhibition. Active in drug development with clinical trial initiatives (e.g., Gremlin1 antibody therapy in Phase I).

• Cancer Research
• Immunology
• Hematology
• +5 more

Dr. Vivien Chen is an Associate Professor at the Concord Clinical School, University of Sydney, and leader of the Platelet and Thrombosis Research Laboratory at the ANZAC Research Institute. She holds clinical roles as a staff specialist haematologist at Concord Repatriation and General Hospital, leading the thrombosis clinic. Her research focuses on platelet biology, coagulation in cancer, and thrombotic mechanisms in cardiovascular diseases, with a translational emphasis on clinical applications. Education: MBBS (University of Sydney), BA, PhD (University of New South Wales), postdoctoral training at Harvard Medical School. Her expertise bridges basic science and clinical practice, particularly in cancer-associated thrombosis and myeloproliferative disorders. Research Interests: Dr. Chen investigates procoagulant platelet formation pathways, mitochondrial function in platelet activation, and thrombotic complications in conditions like coronary artery disease and sepsis. Her work also explores predictive biomarkers for thrombotic outcomes and novel antithrombotic strategies. Awards: Over 15 prestigious awards, including the Eberhard Mammen Young Investigator Award, NHMRC CJ Martin Fellowship, and University Medal for Medicine. Her recognition spans clinical, research, and educational contributions in thrombosis and haematology. Grants & Collaborations: Leads projects funded by NHMRC, National Heart Foundation, and international networks. Collaborates with institutions in Singapore and the UK on thrombosis mechanisms and clinical trials. Current studies include platelet-targeted therapies for coronary artery disease and biomarker discovery in myeloproliferative neoplasms. Labs & Teams: Directs the Platelet and Thrombosis Research Laboratory, integrating vascular biology and clinical haematology research. Engages in interdisciplinary projects with the Sydney Platelet Group and ANZAC Research Institute.

• Platelet Biology
• Coagulation Disorders
• Cancer Thrombosis
• +3 more

Dr Krzysztof Mrozik is an Externally Funded Research Fellow (A) in the School of Biomedicine at the University of Adelaide's Faculty of Health and Medical Sciences. His research focuses on improving treatments for multiple myeloma and bone-tropic cancers, with a particular emphasis on reducing drug side effects and enhancing therapeutic efficacy. He leads a translational research program developing vasculature-targeting agents and nanomedicine formulations to selectively deliver drugs to tumor sites. Affiliations: South Australian Health and Medical Research Institute (SAHMRI), University of Adelaide Collaborations: Researchers across multiple South Australian universities, national/international teams Funding: Over $1.9M in competitive grants His research interests include: Proteasome inhibitor-induced gastrointestinal toxicity mechanisms Role of stromal cell senescence in myeloma progression Enhancing CAR-T cell efficacy in cancer treatment Dr Mrozik co-supervises two PhD students and has published 31 peer-reviewed articles (9 as first author), with a strong citation impact (h-index=22, FWCI=2.0).

• Multiple Myeloma
• Drug Delivery Systems
• Nanomedicine
• +5 more

Adam Irving is a Senior Research Fellow at Monash University's Centre for Health Economics, specializing in health economics and decision modeling. He holds a PhD in Health Economics from Monash University (2020), an MSc in Health Economics & Decision Modelling from the University of Sheffield (2013), and a BEconSc in Economics from the University of Manchester (2009). His research focuses on optimizing healthcare resource allocation, particularly in haematology and blood transfusion practices. He leads the EpiMAP Myeloma project, developing disease pathway models for multiple myeloma using national registry data. Current Projects: Lead modeller for EpiMAP Myeloma (2024–2028) Chief Investigator in GLAM Study (Genomic Liquid Biopsy Analysis for Myeloma, 2024–2028) Co-Investigator in multiple blood management projects (e.g., OPTIMAL Immunoglobulin study) His research interests span economic evaluations of clinical interventions, blood resource stewardship, and translational oncology economics. Recent work includes analyzing transfusion practices in cardiac surgery and sickle cell disease burden in Australia. Publications highlight his expertise in cost-effectiveness analysis, disease modeling, and healthcare system optimization. Ongoing projects aim to refine guidelines for platelet transfusions and immunoglobulin use, with direct implications for UN SDG 3 (Good Health and Well-being). Grants & Collaborations: Projects funded by Australian research councils and partnerships with clinicians, statisticians, and industry Active collaborations across haematology, critical care, and public health disciplines Labs/Teams: Central role in Monash’s Health Economics Centre and cross-faculty teams for disease modeling and translational research.

• Health Economics
• Healthcare Resource Allocation
• Haematology
• +5 more

Professor Andrew Spencer is an Adjunct Professor of Haematology at Monash University and Head of the Malignant Haematology and Stem Cell Transplantation Service at The Alfred Hospital in Melbourne, Australia. He leads the Myeloma Research Group and co-directs the ACRF Blood Cancer Therapeutics Centre at the Australian Centre for Blood Diseases. His research focuses on developing novel therapeutic strategies for multiple myeloma (MM), including drug resistance mechanisms, biomarker identification, and minimal residual disease (MRD) detection. He holds 4 international patents in MM therapeutics and has published over 185 peer-reviewed articles with over 12,600 citations. Key roles include Chair of the Myeloma & Related Diseases Registry (MRDR), Co-ordinating Principal Investigator of the Australasian Myeloma Research Consortium (AMaRC), and member of the International Myeloma Working Group (IMWG). He is an invited investigator for the IMF Black Swan Research Initiative and chairs multiple national and international committees. Research interests span translational research, with emphasis on CD45 phosphatase roles in MM progression, synergistic drug combinations for early-phase clinical trials, and advanced MRD detection techniques. His work contributes to UN Sustainable Development Goals related to health and well-being (SDG 3). Recent projects include the GLAM study (genomic liquid biopsy analysis for MM) and the aMMbition Phase 2 trial evaluating novel treatment sequences for MM patients. He has led over 76 research projects and holds executive roles in organizations like Myeloma Australia and the Australian Haemopoietic Progenitor Cell Transplantation Reference Committee. Scientific awards and recognition include the LRF (UK) Fellowship, Royal Australian College of Physicians Fellowship, and multiple leadership roles in global hematological societies.

• Multiple Myeloma
• Hematology
• Biomarkers of Drug Responsiveness
• +4 more

Nicholas Bingham serves as an Adjunct Research Fellow at the Australian Centre for Blood Diseases, Monash University, focusing on hematological malignancies and diagnostic innovation. His work integrates proteomics, liquid biopsy development, and molecular diagnostics to address challenges in multiple myeloma detection and monitoring. Dr. Bingham's research spans hematology , oncology , and proteomics , with emphasis on: Liquid biopsy optimization for early cancer detection Extracellular vesicle characterization in tumor microenvironments Mass spectrometry-based minimal residual disease assessment Molecular stratification of high-risk myeloma subtypes His publications demonstrate consistent advancement in translating proteomic findings into clinical diagnostics, particularly through blood-based biomarker discovery. Current research trends emphasize non-invasive monitoring techniques, with recent work establishing DNA copy number variations and clonotypic assays as critical tools for identifying smouldering myeloma progression. Collaborative projects integrate flow cytometry, mass spectrometry, and genomic analysis to refine risk stratification models. Dr. Bingham leads the 2024-2025 project Establishing blood-based liquid biopsies for early detection of high-risk multiple myeloma as Primary Chief Investigator, collaborating with Spencer, Reynolds, and Mithraprabhu. This NHMRC-funded initiative builds on his team's prior work in extracellular vesicle proteomics and MYC DNA analysis. His laboratory work centers on the Australian Centre for Blood Diseases' myeloma research program, utilizing: Plasma extracellular vesicle isolation protocols Mass spectrometry clonotypic assays (EasyM) EuroFlow-based minimal residual disease tracking Stromal cell interaction models Future directions include validating liquid biopsy markers for clinical implementation and expanding high-risk myeloma detection to pre-symptomatic stages.

• Hematology
• Oncology
• Liquid Biopsy Development
• +3 more